TD Cowen Sticks to Their Buy Rating for Rapport Therapeutics, Inc. (RAPP)

TipRanksAug 8 14:26 ET · Ratings

Rapport Therapeutics GAAP EPS of -$1.70 Misses by $1.02

Seeking AlphaAug 8 09:33 ET

Express News | Rapport Therapeutics Ended The Quarter With $336.1M In Cash, Cash Equivalents, And Short-term Investments, Excluding Restricted Cash, Which Is Expected To Fund Operations Through The End Of 2026

BenzingaAug 8 07:58 ET

Express News | Rapport Therapeutics Q2 2024 GAAP EPS $(1.70) Misses $(0.68) Estimate

BenzingaAug 8 07:57 ET

Rapport Therapeutics | 10-Q: Quarterly report

SEC announcementAug 8 07:44 ET · Announcements

Rapport Therapeutics: Runway To Fund Operations Through End of 2026 >RAPP

Dow JonesAug 8 07:11 ET